Lazard Asset Management LLC Reduces Stock Holdings in Disc Medicine, Inc. $IRON

Posted by Francis Steltz on Aug 3rd, 2026

Lazard Asset Management LLC cut its holdings in Disc Medicine, Inc. (NASDAQ:IRON – Free Report) by 32.1% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,400 shares of the company’s stock after selling 18,653 shares during the period. Lazard Asset Management LLC’s holdings in Disc Medicine were worth $2,519,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in IRON. ANTIPODES PARTNERS Ltd purchased a new position in Disc Medicine during the 4th quarter valued at about $33,000. KBC Group NV purchased a new stake in shares of Disc Medicine in the fourth quarter valued at about $80,000. Persistent Asset Partners Ltd acquired a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $141,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after purchasing an additional 490 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Disc Medicine by 15,137.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after purchasing an additional 2,422 shares in the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, insider Rahul Khara sold 7,500 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00. Following the transaction, the insider owned 52,173 shares of the company’s stock, valued at $3,663,588.06. This represents a 12.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Jonathan Yen-Wen Yu sold 18,612 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $69.19, for a total value of $1,287,764.28. Following the sale, the chief operating officer owned 54,324 shares in the company, valued at $3,758,677.56. This trade represents a 25.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 105,712 shares of company stock worth $7,597,536. Insiders own 3.76% of the company’s stock.

Disc Medicine Stock Performance

Shares of NASDAQ IRON opened at $77.00 on Monday. The company has a market cap of $2.94 billion, a PE ratio of -11.70 and a beta of 1.00. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The company has a 50-day simple moving average of $72.74 and a 200-day simple moving average of $69.62.

Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.17. On average, equities analysts anticipate that Disc Medicine, Inc. will post -6.75 earnings per share for the current year.

Wall Street Analyst Weigh In

IRON has been the topic of a number of recent research reports. Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday. Wedbush reissued an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Morgan Stanley boosted their price target on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $104.44.

View Our Latest Research Report on IRON

Disc Medicine Profile

(Free Report)

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.